April 17, 2020
A California federal judge on Friday granted two whistleblowers' bid to toss their decade-old multibillion-dollar False Claims Act suit against Gilead Sciences Inc. from federal court and allow them to pursue claims in state court, rejecting Gilead's arguments that the relators are forum shopping and "running away" from its motion to dismiss.
November 15, 2019
The U.S. Department of Justice's controversial crusade against disfavored False Claims Act suits appears to be on increasingly solid ground after a series of court decisions allowing the DOJ to end whistleblower FCA cases. Here, Law360 spotlights five key takeaways from the government's recent success.
August 01, 2019
A California federal judge weighing whether to grant the U.S. Department of Justice's bid to scrap whistleblowers' decade-long, multibillion-dollar False Claims Act suit against Gilead Sciences Inc. has suggested that DOJ attorneys brief him on any cost-benefit analysis they performed in deciding to seek dismissal.
April 17, 2019
The U.S. Department of Justice's newly launched campaign to shrink its False Claims Act docket has hit surprising turbulence as federal judges scrutinize the DOJ's willingness to look the other way on alleged fraud and its disparagement of a company that specializes in bringing FCA cases.
March 29, 2019
The U.S. Department of Justice has asked a California federal judge to nix a prominent False Claims Act case linking Gilead Sciences Inc. to sketchy drug manufacturing, following through on a vow the U.S. Department of Justice made toward the end of 2018.
June 15, 2015
Changes to a False Claims Act lawsuit alleging Gilead Sciences Inc. sought Medicare and Medicaid reimbursement for shoddily made drugs were not enough to save it in California federal court Friday, according to a decision nixing the case for want of any FCA violations.
March 20, 2015
Gilead Sciences Inc. is pressing a California federal court to wipe out a False Claims Act suit brought by former quality control staffers, arguing that allegations of shoddy drugmaking fail to show deception of Medicare and Medicaid or sales of truly worthless products.
January 08, 2015
A California federal judge on Wednesday tossed allegations that Gilead Sciences Inc. cheated the government by selling contaminated and defective drugs to Medicare and Medicaid, finding the whistleblowers failed to state a claim under the False Claims Act.
September 11, 2014
Gilead Sciences Inc. cheated taxpayers by selling contaminated and defective drugs to Medicare and Medicaid, whistleblowers charged in a False Claims Act lawsuit unsealed Wednesday in California federal court, adding to rising fraud litigation over alleged manufacturing violations.